Clinical Trials Logo

Gout Chronic clinical trials

View clinical trials related to Gout Chronic.

Filter by:
  • None
  • Page 1

NCT ID: NCT05253833 Active, not recruiting - Gout Clinical Trials

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

Start date: August 12, 2022
Phase: Phase 2
Study type: Interventional

This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.

NCT ID: NCT05119686 Completed - Gout Clinical Trials

Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients

Start date: November 16, 2021
Phase: Phase 2
Study type: Interventional

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 weeks.

NCT ID: NCT03303989 Completed - Gout Chronic Clinical Trials

REduCing Immunogenicity to PegloticasE (RECIPE) Study

RECIPE
Start date: June 14, 2018
Phase: Phase 2
Study type: Interventional

Pegloticase treatment for chronic refractory gout is limited by immunogenicity. The investigators propose the REduCing Immunogenicity to PegloticasE (RECIPE) trial to begin to investigate the question of whether a short course of immune modulating therapy with mycophenolate mofetil can significantly and safely attenuate immunogenicity to pegloticase and ensure patients afflicted with chronic refractory gout have better treatment outcomes and improved quality of life.

NCT ID: NCT02959918 Completed - Hyperuricemia Clinical Trials

Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

Start date: October 2016
Phase: Phase 2
Study type: Interventional

This is an open label multicenter study to evaluate the safety and tolerability of multiple doses (3 monthly IV infusions) of SEL-212 ( a combination of pegsiticase (SEL-037) and SVP-rapamycin (SEL-110)) followed by multiple doses (2 monthly IV infusions) of pegsiticase (SEL-037) alone for a total of 5 treatment cycles in subjects with symptomatic gout and hyperuricemia. Additional participants will be treated with multiple doses ( 5 monthly IV infusions) of pegsiticase (SEL-037) alone. Participants will be monitored for safety endpoints through the 5th treatment cycle plus 30 days .Pharmacokinetic samples will be drawn at pre-determined time points in addition to weekly serum uric acid levels.